Tissue factor-activated factor VII complex (TF-FVIIa)

The Tissue factor-activated factor VII (TF-FVIIa) complex, also known as the extrinsic tenase complex, is the primary physiological initiator of the blood coagulation cascade (StatPearls, 2023). It is formed upon vascular injury when the transmembrane protein Tissue Factor (TF/CD142) is exposed to and binds circulating Factor VII or its activated form, Factor VIIa (UniProt P13726). Once assembled on a phospholipid surface, this complex proteolytically activates Factor IX and Factor X, which are critical steps in the generation of thrombin and the subsequent formation of a stable fibrin clot (PubMed: 15141316). Beyond its central role in hemostasis, the TF-FVIIa complex triggers intracellular signaling pathways by cleaving Protease-Activated Receptors (PARs), particularly PAR2 (PubMed: 22431271). This signaling activity influences a variety of biological processes, including inflammation, angiogenesis, and tumor cell migration and metastasis (PubMed: 19136618). In pathological states, aberrant expression of TF and overactivity of the TF-FVIIa complex are linked to arterial and venous thrombosis, as well as the progression of various cancers (PubMed: 21854337). Therapeutic strategies targeting this complex include monoclonal antibodies like Tisotumab vedotin for cancer and various inhibitors for thrombotic disorders (DrugBank DB15584).

Other names

Extrinsic tenase complexTissue factor-Factor VIIa complexTF-FVIIa complexCoagulation factor III-activated factor VII complexCD142-FVIIa complexTF:VIIa complex

The mechanism of action for drugs targeting the Tissue factor-activated factor VII complex involves inhibiting the initiation of the extrinsic pathway of coagulation. Direct inhibitors bind to the active site or exosite of the complex to prevent the proteolytic cleavage of Factor IX and Factor X. Monoclonal antibodies may block the interaction between Tissue Factor and Factor VIIa or target the Tissue Factor protein itself to deliver cytotoxic agents or inhibit downstream signaling through Protease-Activated Receptors (PARs). By suppressing these pathways, these drugs reduce thrombin generation, prevent clot formation, and may inhibit tumor-associated angiogenesis and metastasis.